Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.00 USD
Change Today -0.11 / -1.36%
Volume 370.4K
BCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:52 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$8.14
Previous Close
$8.11
Day High
$8.40
Day Low
$7.95
52 Week High
08/11/14 - $14.62
52 Week Low
05/8/14 - $7.29
Market Cap
575.7M
Average Volume 10 Days
1.1M
EPS TTM
$-0.63
Shares Outstanding
72.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

50 Employees
Last Reported Date: 03/2/15
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $475.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $387.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $418.9K
Senior Vice President of Drug Discovery
Total Annual Compensation: $341.5K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $231.7K
Compensation as of Fiscal Year 2013.

biocryst pharmaceuticals inc (BCRX) Key Developments

Peder K. Jensen Not to Stand for Re-Election of Biocryst Pharmaceuticals, Inc.'s Board of Directors

On March 4, 2015, Peder K. Jensen, gave notice that he will not stand for re-election to the Board of Directors of BioCryst Pharmaceuticals, Inc. at the company's 2015 Annual Meeting to be held in May, when his current term ends. Dr. Jensen cited no disagreement on any matter relating to the company, its operations, policies or practices.

BioCryst Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 10:45 AM

BioCryst Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 10:45 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Jon P. Stonehouse, Chief Executive Officer, President and Executive Director.

BioCryst Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Net Operating Cash Guidance for the Full Year of 2015

BioCryst Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the three months ended December 31, 2014, total revenues decreased to $5.4 million from $10.6 million in the fourth quarter of 2013. The decrease in revenues resulted primarily from the June 2014 expiration and related completion of development activities under the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) peramivir development contract. The net loss for the fourth quarter of 2014 was $11.7 million, or $0.16 per share, compared to a net loss of $5.4 million, or $0.09 per share, for the fourth quarter 2013. Loss from operations was $15,156,000 against $6,334 a year ago. For the year ended December 31, 2014, total revenues decreased to $13.6 million from $17.3 million in 2013. The decrease was primarily the result of the June 2014 contract expiration and completion of activities under the BARDA/HHS peramivir development contract. The net loss for 2014 increased to $45.2 million or $0.68 per share, compared to a net loss of $30.1 million, or $0.55 per share for 2013. Net operating cash use for 2014 was $33.3 million as compared to $22.8 million utilized in 2013. Loss from operations was $45,771,000 against $30,717 a year ago. The company is expecting its 2015 net operating cash use to be in the range of $65 to $80 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $8.00 USD -0.11

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥1,924 JPY -60.50
Dyax Corp $16.55 USD +0.35
Pharming Group NV €0.34 EUR -0.011
Salix Pharmaceuticals Ltd $172.69 USD +0.055
Shire PLC 5,425 GBp +115.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.8x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.